JP2024525800A5 - - Google Patents

Info

Publication number
JP2024525800A5
JP2024525800A5 JP2024502055A JP2024502055A JP2024525800A5 JP 2024525800 A5 JP2024525800 A5 JP 2024525800A5 JP 2024502055 A JP2024502055 A JP 2024502055A JP 2024502055 A JP2024502055 A JP 2024502055A JP 2024525800 A5 JP2024525800 A5 JP 2024525800A5
Authority
JP
Japan
Application number
JP2024502055A
Other languages
Japanese (ja)
Other versions
JP2024525800A (ja
JPWO2023284559A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/103049 external-priority patent/WO2023284559A1/zh
Publication of JP2024525800A publication Critical patent/JP2024525800A/ja
Publication of JP2024525800A5 publication Critical patent/JP2024525800A5/ja
Publication of JPWO2023284559A5 publication Critical patent/JPWO2023284559A5/ja
Pending legal-status Critical Current

Links

JP2024502055A 2021-07-16 2022-06-30 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 Pending JP2024525800A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110807464 2021-07-16
CN202110807464.3 2021-07-16
PCT/CN2022/103049 WO2023284559A1 (zh) 2021-07-16 2022-06-30 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途

Publications (3)

Publication Number Publication Date
JP2024525800A JP2024525800A (ja) 2024-07-12
JP2024525800A5 true JP2024525800A5 (https=) 2025-07-03
JPWO2023284559A5 JPWO2023284559A5 (https=) 2025-07-03

Family

ID=84919019

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024502055A Pending JP2024525800A (ja) 2021-07-16 2022-06-30 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用

Country Status (10)

Country Link
US (1) US20240325428A1 (https=)
EP (1) EP4372085A4 (https=)
JP (1) JP2024525800A (https=)
KR (1) KR20240034787A (https=)
CN (2) CN117580953B (https=)
AU (1) AU2022309416A1 (https=)
CA (1) CA3225015A1 (https=)
MX (1) MX2024000650A (https=)
TW (1) TW202321450A (https=)
WO (1) WO2023284559A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025520796A (ja) * 2022-06-27 2025-07-03 大睿生物 アポリポタンパク質C3発現を阻害するsiRNA
WO2024188174A1 (zh) * 2023-03-10 2024-09-19 苏州瑞博生物技术股份有限公司 一种药物组合物及其用途
TW202508607A (zh) * 2023-05-19 2025-03-01 大陸商北京炫景瑞醫藥科技有限公司 雙股寡核苷酸及其共軛物和用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009082607A2 (en) 2007-12-04 2009-07-02 Alnylam Pharmaceuticals, Inc. Targeting lipids
CA2750561C (en) * 2009-01-26 2017-10-10 Protiva Biotherapeutics, Inc. Compositions and methods for silencing apolipoprotein c-iii expression
US20120136073A1 (en) 2010-11-15 2012-05-31 Life Technologies Corporation Amine-Containing Transfection Reagents and methods for making and using same
AU2013299717B2 (en) 2012-08-06 2018-06-28 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugated RNA agents and process for their preparation
EP3564374A1 (en) * 2013-06-21 2019-11-06 Ionis Pharmaceuticals, Inc. Compositions and methods for modulation of target nucleic acids
JP6702862B2 (ja) 2013-07-11 2020-06-03 アルニラム ファーマスーティカルズ インコーポレイテッドAlnylam Pharmaceuticals, Inc. オリゴヌクレオチド−リガンドコンジュゲートおよびそれらの調製方法
EP3052627B1 (en) * 2013-10-04 2018-08-22 Novartis AG Novel formats for organic compounds for use in rna interference
WO2015168661A1 (en) * 2014-05-01 2015-11-05 Smith Larry J METHODS AND MODIFICATIONS THAT PRODUCE ssRNAi COMPOUNDS WITH ENHANCED ACTIVITY, POTENCY AND DURATION OF EFFECT
EP3736334A1 (en) * 2014-07-16 2020-11-11 Arrowhead Pharmaceuticals, Inc. Rnai compositions to treat apoc3-related diseases
JP2018511555A (ja) * 2015-02-27 2018-04-26 アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. リポジストロフィー集団におけるアポリポタンパク質C−III(ApoCIII)発現の調節
JP2020522265A (ja) * 2017-06-02 2020-07-30 ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. オリゴヌクレオチド組成物及びその使用方法
US10597657B2 (en) * 2017-09-11 2020-03-24 Arrowhead Pharmaceuticals, Inc. RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)
CA3083968C (en) 2017-12-01 2024-04-23 Suzhou Ribo Life Science Co., Ltd. Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof
JP7365052B2 (ja) * 2017-12-01 2023-10-19 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
EP3732185B1 (en) 2017-12-29 2025-02-26 Suzhou Ribo Life Science Co., Ltd. Conjugates and preparation and use thereof
US12496347B2 (en) * 2018-12-28 2025-12-16 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
WO2021067744A1 (en) * 2019-10-02 2021-04-08 Dicerna Pharmaceuticals, Inc. Chemical modifications of small interfering rna with minimal fluorine content
CN112876534B (zh) * 2019-11-29 2024-02-09 苏州瑞博生物技术股份有限公司 肝靶向化合物及缀合物

Similar Documents

Publication Publication Date Title
JP2024525800A5 (https=)
BR102022023461A2 (https=)
BR202022009269U2 (https=)
BY13163U (https=)
CN307049114S (https=)
CN307049105S (https=)
CN307046752S (https=)
CN307046676S (https=)
CN307046354S (https=)
CN307045619S (https=)
CN307045529S (https=)
CN307045387S (https=)
CN307045253S (https=)
CN307045090S (https=)
CN307045082S (https=)
CN307044376S (https=)
CN307044351S (https=)
BY23963C1 (https=)
BY13176U (https=)
BY13175U (https=)
BY13174U (https=)
BY13172U (https=)
BY13170U (https=)
BY13169U (https=)
BY13168U (https=)